Search results for "double-blind method"

showing 10 items of 631 documents

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised…

2015

Elevated numbers of blood eosinophils are a risk factor for asthma exacerbations. Reslizumab is a humanised anti-interleukin 5 monoclonal antibody that disrupts eosinophil maturation and promotes programmed cell death. We aimed to assess the efficacy and safety of reslizumab in patients with inadequately controlled, moderate-to-severe asthma.We did two duplicate, multicentre, double-blind, parallel-group, randomised, placebo-controlled phase 3 trials. Both trials enrolled patients with asthma aged 12-75 years (from 128 clinical research centres in study 1 and 104 centres in study 2) from Asia, Australia, North America, South America, South Africa, and Europe, whose asthma was inadequately c…

AdultMalePulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyAsiaAntibodies Monoclonal HumanizedPlaceboLebrikizumablaw.inventionSouth Africachemistry.chemical_compoundDouble-Blind MethodRandomized controlled trialReslizumablawmedicineHumansAsthmaIntention-to-treat analysisbusiness.industryAustraliaMiddle AgedSouth Americamedicine.diseaseBenralizumabAsthmaEosinophilsEuropeClinical trialTreatment OutcomechemistryNorth AmericaFemalebusinessmedicine.drugThe Lancet Respiratory Medicine
researchProduct

Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma

2013

Tiotropium, a once-daily long-acting anticholinergic bronchodilator, when administered via Respimat® SoftMist™ inhaler (tiotropium Respimat®) significantly reduces the risk of severe exacerbations and improves lung function in patients with severe persistent asthma that is not fully controlled despite using inhaled corticosteroids (ICS) and long-acting β2-agonists. To further explore the dose–response curve in asthma, we investigated the efficacy and safety of three different doses of tiotropium Respimat® as add-on to ICS in symptomatic patients with moderate persistent asthma. In this randomised, double-blind, placebo-controlled, four-way crossover study, patients were randomised to tiotro…

AdultMalePulmonary and Respiratory MedicineRespimatmedicine.drug_classScopolamine DerivativesPlaceboFEV1/FVC ratioDouble-Blind MethodCholinergic antagonistsBronchodilatorAdministration InhalationmedicineHumansTiotropium BromideAsthmaCross-Over StudiesDose-Response Relationship Drugbusiness.industryResearchTiotropiumTiotropium bromideMiddle AgedBronchodilator agentsmedicine.diseaseDose-ranging studyCrossover studyAsthmaRespimatrespiratory tract diseasesClinical trialAnesthesiaFemalebusinessmedicine.drugFollow-Up StudiesRespiratory Research
researchProduct

Effect of Salmeterol on Seasonal Changes in Airway Responsiveness and Exhaled Nitric Oxide in Pollen-Sensitive Asthmatic Subjects

2002

Objective Using a model of natural allergen exposure, we examined the effect of regular treatment with salmeterol on allergen-induced changes in airway responsiveness and exhaled nitric oxide (ENO). Design Double-blind, randomized, parallel-group study. Setting Specialist allergy unit in a university hospital. Patients Asthmatic patients sensitized to pollen allergens were randomly allocated to monotherapy with salmeterol (n = 14) or placebo (n = 13). Interventions Salmeterol, 25 μg, and placebo inhalers, two puffs bid, for 6 weeks. Measurements Spirometry, the level of a provocative concentration of a substance (methacholine) causing a 20% fall in FEV 1 (PC 20 ), the PC 20 level for adenos…

AdultMalePulmonary and Respiratory MedicineSpirometrymedicine.medical_specialtyAdolescentmedicine.drug_classNitric OxideCritical Care and Intensive Care MedicinePlaceboDouble-Blind MethodForced Expiratory VolumeInternal medicineBronchodilatorAdministration InhalationmedicineHumansAlbuterolExpirationSalmeterol XinafoateAsthmamedicine.diagnostic_testbusiness.industryAirway ResistanceRhinitis Allergic SeasonalMiddle Agedrespiratory systemmedicine.diseaseAdenosine MonophosphateAsthmarespiratory tract diseasesEndocrinologyBreath TestsExhaled nitric oxideFemaleMethacholineSeasonsSalmeterolCardiology and Cardiovascular Medicinebusinessmedicine.drugChest
researchProduct

Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: The BRIGHT study

2014

Summary Introduction QVA149 is a novel, inhaled, once-daily dual bronchodilator containing a fixed-dose combination of the long-acting β 2 -agonist indacaterol and the long-acting muscarinic antagonist glycopyrronium (NVA237), for the treatment of chronic obstructive pulmonary disease (COPD). This study evaluated the effects of QVA149 on exercise tolerance, hyperinflation, lung function and lung volumes versus placebo and tiotropium. Methods Patients with moderate-to-severe COPD were randomized to QVA149 110/50 μg, placebo or tiotropium 18 μg once daily in a blinded, 3-period crossover study for 3 weeks. The primary endpoint was exercise endurance time at Day 21 for QVA149 versus placebo. R…

AdultMalePulmonary and Respiratory Medicinemedicine.drug_classVital CapacityScopolamine DerivativesHyperinflationQuinolonesPlaceboDrug Administration SchedulePulmonary Disease Chronic ObstructiveFunctional residual capacityDouble-Blind MethodForced Expiratory VolumeBronchodilatormedicineClinical endpointHumansLung volumesTiotropium BromideExerciseAgedCOPDCross-Over StudiesExercise Tolerancebusiness.industryChronic obstructive pulmonary diseaseTiotropiumQVA149Middle Agedmedicine.diseaseGlycopyrrolateCrossover studyBronchodilator Agentsrespiratory tract diseasesDrug CombinationsTreatment OutcomeSpirometryAnesthesiaIndansIndacaterolFemaleLung Volume Measurementsbusinessmedicine.drugRespiratory Medicine
researchProduct

A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in pa…

2019

Abstract Introduction Mometasone furoate (MF) is the inhaled corticosteroid (ICS) component in the long-acting β2-agonist (LABA)/ICS fixed-dose combination of indacaterol/MF, delivered via Breezhaler®, in development for asthma. MF at low (80 μg) and high (320 μg) doses delivered via Breezhaler® is expected to be comparable to MF at low (200 μg) and high (800 μg) doses respectively, delivered via Twisthaler®. Methods This was a randomized, double-blind, double-dummy, four-week, parallel-group study of 739 adolescents and adults with persistent asthma. Eligible patients were receiving ICS treatment up to the maximum dose per day on a stable regimen for at least four weeks before screening. T…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentmedicine.drug_classUrologyMometasone furoateRandom AllocationYoung Adult03 medical and health sciences0302 clinical medicineDouble-Blind MethodAdrenal Cortex HormonesAdministration InhalationmedicineClinical endpointHumansPharmacology (medical)Anti-Asthmatic Agents030212 general & internal medicineAdverse effectLungAgedAsthmaAged 80 and overbusiness.industryBiochemistry (medical)Middle Agedmedicine.diseaseAsthmaDrug CombinationsRegimenTreatment Outcome030228 respiratory systemAsthma Control QuestionnaireCorticosteroidIndacaterolFemalebusinessMometasone Furoatemedicine.drugPulmonary Pharmacology & Therapeutics
researchProduct

Analysis of sleep EEG microstructure in subchronic paroxetine treatment of healthy subjects

1997

Paroxetine is a selective and potent serotonin reuptake inhibitor and its efficacy for the treatment of depression has been proven. Under acute and subchronical treatment regimens, disturbances of the regular sleep pattern are a reported side effect of the drug. The present study was therefore performed to investigate the impact of subchronic treatment with the selective serotonin reuptake inhibitor paroxetine on the microstructure of the sleep EEG. The study especially addressed the question of subchronic effects of paroxetine medication (30 mg/day) in eight healthy male volunteers in a double blind, placebo-controlled crossover design. Conventional sleep EEG parameters and a spectral powe…

AdultMaleSerotonin reuptake inhibitorElectroencephalographyNon-rapid eye movement sleepDouble-Blind MethodmedicineHumansPharmacologySleep StagesSleep disorderCross-Over Studiesmedicine.diagnostic_testElectroencephalographymedicine.diseaseParoxetineSleep in non-human animalsParoxetineDelta RhythmAnesthesiaAntidepressive Agents Second-GenerationBeta RhythmSleepPsychologyReuptake inhibitorSelective Serotonin Reuptake Inhibitorsmedicine.drugPsychopharmacology
researchProduct

Serotonergic modulation of response inhibition and re-engagement? Results of a study in healthy human volunteers

2010

Objective Cognitive functions dependent on the prefrontal cortex, such as the ability to suppress behavior (response inhibition) and initiate a new one (response re-engagement) is important in the activities of daily life. Central serotonin (5-HT) function is thought to be a critical component of these cognitive functions. In recent studies, 5-HT failed to affect stop-signal reaction time (SSRT), a fundamental process in behavioral inhibition. We were interested if response inhibition and re-engagement are influenced through central 5-HT activity as mediated via the 5-HT transporter. Methods Here, using a stop-change task, we investigated the effects of acute and repeated treatment with 10 …

AdultMaleSerotoninCitalopramCitalopramSerotonergicDrug Administration ScheduleDevelopmental psychologyDouble-Blind MethodReaction TimemedicineHumansEscitalopramPharmacology (medical)Prefrontal cortex5-HT receptorCross-Over StudiesDose-Response Relationship DrugCognitionInhibition PsychologicalPsychiatry and Mental healthNeurologyNeurology (clinical)SerotoninReuptake inhibitorPsychologyNeuroscienceSelective Serotonin Reuptake Inhibitorsmedicine.drugHuman Psychopharmacology: Clinical and Experimental
researchProduct

Early and late histamine release induced by albumin, hetastarch and polygeline: some unexpected findings.

2003

Objective: The perioperative use of colloidal plasma substitutes is still under discussion. We therefore conducted a prospective randomised study with three commonly used plasma substitutes to examine their histamine releasing effects in 21 volunteers. Material or subjects: 21 male volunteers were enrolled in this prospective, randomised, controlled clinical study. Endpoints were the incidence of early and late histamine release and the time course of the release kinetics. Normovolemic hemodilution technique was used with hydroxyethyl starch (n = 6), human albumin (n = 6) and polygeline (n = 9). Measurement and observation period was 240 min after the start of the plasma substitute infusion…

AdultMaleSide effectImmunologyPlasma SubstitutesBlood PressureHydroxyethyl starchPlasma SubstitutesHistamine ReleaseHydroxyethyl Starch Derivativeschemistry.chemical_compoundDouble-Blind MethodHeart RateIntensive carePolygelinemedicineHumansSerum AlbuminHetastarchAgedPharmacologyHemodilutionChemistryAlbuminHemodynamicsMiddle AgedAnesthesiaPolygelineHistaminemedicine.drugHistamineInflammation research : official journal of the European Histamine Research Society ... [et al.]
researchProduct

Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately c…

2009

SUMMARY Aims: To evaluate the efficacy of switching from a previous statin monotherapy to ezetimibe ⁄simvastatin (EZE ⁄SIMVA) 10 ⁄20 mg vs. rosuvastatin (ROSUVA) 10 mg. Methods: In this randomised, double-blind study, 618 patients with documented hypercholesterolaemia [low-density lipoprotein cholesterol (LDL-C) ‡ 2.59 and £ 4.92 mmol ⁄l] and with high cardiovascular risk who were taking a stable daily dose of one of several statin medications for ‡ 6 weeks prior to the study randomisation visit entered a 6-week open-label stabilisation ⁄screening period during which they continued to receive their prestudy statin dose. Following stratification by study site and statin dose ⁄potency, patien…

AdultMaleSimvastatinmedicine.medical_specialtyimvastatinStatinmedicine.drug_classHypercholesterolemiaCoronary Artery DiseaseGastroenterologyhypercholesterolaemicchemistry.chemical_compoundDouble-Blind MethodEzetimibeRisk FactorsInternal medicinemedicineHumansRosuvastatinRosuvastatin CalciumAgedAged 80 and overSulfonamidesbiologybusiness.industryCholesterolCholesterol LDLGeneral MedicineMiddle AgedFluorobenzenesRosuvastatin CalciumPyrimidinesTreatment OutcomeEndocrinologychemistrySimvastatinHMG-CoA reductasebiology.proteinAzetidinesDrug Therapy CombinationFemalelipids (amino acids peptides and proteins)Ezetimibe/simvastatinHydroxymethylglutaryl-CoA Reductase Inhibitorsbusinessezetimibemedicine.drugInternational Journal of Clinical Practice
researchProduct

S-Ketamine-Induced NMDA Receptor Blockade during Natural Speech Production and Its Implications for Formal Thought Disorder in Schizophrenia: A Pharm…

2017

Structural and functional changes in the lateral temporal language areas have been related to formal thought disorder (FTD) in schizophrenia. Continuous, natural speech production activates the right lateral temporal lobe in schizophrenia, as opposed to the left in healthy subjects. Positive and negative FTD can be elicited in healthy subjects by glutamatergic NMDA blockade with ketamine. It is unclear whether the glutamate system is related to the reversed hemispheric lateralization during speaking in patients. In a double-blind, crossover, placebo-controlled study, 15 healthy, male, right-handed volunteers overtly described 7 pictures for 3 min each while BOLD signal changes were acquired…

AdultMaleSpeech productionmedicine.medical_specialtyAudiologyReceptors N-Methyl-D-AspartateBrain mappingPsychoses Substance-InducedLateralization of brain functionTemporal lobeThinking03 medical and health sciencesGlutamatergic0302 clinical medicineDouble-Blind Methodmental disordersmedicineHumansSpeechPsychiatryPharmacologyBrain MappingPsychotropic DrugsCross-Over StudiesThought disorderBrainmedicine.diseaseMagnetic Resonance Imaging030227 psychiatryOxygenPsychiatry and Mental healthSchizophreniaCerebrovascular CirculationVisual PerceptionNMDA receptorKetamineSchizophrenic PsychologyOriginal Articlemedicine.symptomPsychologyExcitatory Amino Acid Antagonists030217 neurology & neurosurgeryNeuropsychopharmacology
researchProduct